Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Checkpoint Therapeutics (CKPT) Share Price

Share on StockTwits

Media headlines about Checkpoint Therapeutics (NASDAQ:CKPT) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.6672006988645 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

CKPT has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Checkpoint Therapeutics in a report on Wednesday. Zacks Investment Research lowered shares of Checkpoint Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 11th. Finally, ValuEngine upgraded shares of Checkpoint Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

Shares of CKPT traded up $0.58 during midday trading on Friday, reaching $3.75. The stock had a trading volume of 315,162 shares, compared to its average volume of 44,536. Checkpoint Therapeutics has a 1-year low of $2.22 and a 1-year high of $10.50. The firm has a market capitalization of $101.49 million, a price-to-earnings ratio of -3.75 and a beta of -0.07.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings results on Tuesday, August 7th. The company reported ($0.23) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.09. Checkpoint Therapeutics had a negative net margin of 2,367.51% and a negative return on equity of 126.68%. The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.37 million. equities research analysts expect that Checkpoint Therapeutics will post -1.18 EPS for the current year.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.

See Also: What is the Book Value of a Share?

Insider Buying and Selling by Quarter for Checkpoint Therapeutics (NASDAQ:CKPT)

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.